The role of natural killer cells in pulmonary immunosurveillance

Frontiers in Bioscience - Scholar

Volumn 5 S, Issue 2, 2013, Pages 575-587

  Hesker, Pamela Rose ^a   Krupnick, Alexander Sasha ^a  

^a Washington University in St Louis School of Medicine   (United States)

Author keywords

Immunosurveillance; Lung cancer; Natural killer cell; Review; Tumor immunology

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FALIMAREV; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; IPILIMUMAB; K RAS PROTEIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MUCIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR;

ADAPTIVE IMMUNITY; BACTERIAL INFECTION; BREAST METASTASIS; CANCER RISK; CANCER SURVIVAL; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CYTOKINE PRODUCTION; DRUG MEGADOSE; EFFECTOR CELL; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INNATE IMMUNITY; KIDNEY METASTASIS; LUNG; LUNG CANCER; LUNG INFECTION; LUNG METASTASIS; LYMPHOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC MELANOMA; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

RODENTIA;

EID: 84884323161     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s391     Document Type: Review

References (87)

1. R Kiessling, E Klein, H Pross and H Wigzell: "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol, 5(2), 117-21 (1975)
2. HF Pross and M Jondal: Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. Clin Exp Immunol, 21(2), 226-35 (1975)
3. WH West, GB Cannon, HD Kay, GD Bonnard and RB Herberman: Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol, 118(1), 355-61 (1977)
4. WM Yokoyama: Natural Killer Cells. In: Fundamental Immunology. Ed WE Paul. (2008)
5. MA Cooper, TA Fehniger and MA Caligiuri: The biology of human natural killer-cell subsets. Trends Immunol, 22(11), 633-40 (2001)
6. FJ Culley: Natural killer cells in infection and inflammation of the lung. Immunology, 128(2), 151-63 (2009)
7. DG Hesslein and LL Lanier: Transcriptional control of natural killer cell development and function. Adv Immunol, 109, 45-85 (2011)
8. MJ Smyth, GP Dunn and RD Schreiber: Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol, 90, 1-50 (2006)
9. R Meazza, B Azzarone, AM Orengo and S Ferrini: Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol, 2011, 861920 (2011)
10. M Recher, LJ Berglund, DT Avery, MJ Cowan, AR Gennery, J Smart, J Peake, M Wong, SY Pai, S Baxi, JE Walter, U Palendira, GA Tangye, M Rice, S Brothers, W Al-Herz, H Oettgen, H Eibel, JM Puck, F Cattaneo, JB Ziegler, S Giliani, SG Tangye and LD Notarangelo: IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood, 118(26), 6824-35 (2011)
11. H Spits and T Cupedo: Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol, 30, 647-75 (2012)
12. M Cherrier, C Ohnmacht, S Cording and G Eberl: Development and function of intestinal innate lymphoid cells. Curr Opin Immunol, 24(3), 277-83 (2012)
13. L Moretta and A Moretta: Killer immunoglobulin-like receptors. Curr Opin Immunol, 16(5), 626-33 (2004)
14. WM Yokoyama and BF Plougastel: Immune functions encoded by the natural killer gene complex. Nat Rev Immunol, 3(4), 304-16 (2003)
15. DA Higuchi, P Cahan, J Gao, ST Ferris, J Poursine-Laurent, TA Graubert and WM Yokoyama: Structural variation of the mouse natural killer gene complex. Genes Immun, 11(8), 637-48 (2010)
16. A Garcia-Lora, I Algarra and F Garrido: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol, 195(3), 346-55 (2003)
17. K Karre, HG Ljunggren, G Piontek and R Kiessling: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature, 319(6055), 675-8 (1986)
18. HG Ljunggren, K Sturmhofel, E Wolpert, GJ Hammerling and K Karre: Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol, 145(1), 380-6 (1990)
19. S Kim, J Poursine-Laurent, SM Truscott, L Lybarger, YJ Song, L Yang, AR French, JB Sunwoo, S Lemieux, TH Hansen and WM Yokoyama: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature, 436(7051), 709-13 (2005)
20. HJ Pegram, DM Andrews, MJ Smyth, PK Darcy and MH Kershaw: Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol, 89(2), 216-24 (2011)
21. NT Joncker, NC Fernandez, E Treiner, E Vivier and DH Raulet: NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: The rheostat model. J Immunol, 182(8), 4572-80 (2009)
22. E Vivier, E Tomasello, M Baratin, T Walzer and S Ugolini: Functions of natural killer cells. Nat Immunol, 9(5), 503-10 (2008)
23. LL Lanier: NK cell receptors. Annu Rev Immunol, 16, 359-93 (1998)
24. A Fuchs and M Colonna: The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol, 16(5), 359-66 (2006)
25. TA Fehniger, SF Cai, X Cao, AJ Bredemeyer, RM Presti, AR French and TJ Ley: Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity, 26(6), 798-811 (2007)
26. ND Huntington, CA Vosshenrich and JP Di Santo: Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol, 7(9), 703-14 (2007)
27. IJ Puzanov, M Bennett and V Kumar: IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol, 157(10), 4282-5 (1996)
28. MA Cooper, JM Elliott, PA Keyel, L Yang, JA Carrero and WM Yokoyama: Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A, 106(6), 1915-9 (2009)
29. GR Hook, MA Greenwood, D Barba, B Ikejiri, SN Chen, EH Oldfield, RJ Weber and LM Muul: Morphology of interleukin-2-stimulated human peripheral blood mononuclear effector cells killing glioma-derived tumor cells in vitro. J Natl Cancer Inst, 80(3), 171-7 (1988)
30. J Martinez, X Huang and Y Yang: Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog, 6(3), e1000811 (2010)
31. S Sivori, M Falco, M Della Chiesa, S Carlomagno, M Vitale, L Moretta and A Moretta: CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A, 101(27), 10116-21 (2004)
32. OM Hart, V Athie-Morales, GM O'Connor and CM Gardiner: TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol, 175(3), 1636-42 (2005)
33. S McCartney, W Vermi, S Gilfillan, M Cella, TL Murphy, RD Schreiber, KM Murphy and M Colonna: Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med, 206(13), 2967-76 (2009)
34. A Komiyama, H Kawai, A Yabuhara, M Yanagisawa, Y Miyagawa, M Ota, H Hasekura and T Akabane: Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Pediatrics, 85(3), 323-30 (1990)
35. SY Al Omar, E Marshall, D Middleton and SE Christmas: Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology, 133(1), 94-104 (2011)
36. NF Delahaye, S Rusakiewicz, I Martins, C Menard, S Roux, L Lyonnet, P Paul, M Sarabi, N Chaput, M Semeraro, V Minard-Colin, V Poirier-Colame, K Chaba, C Flament, V Baud, H Authier, S Kerdine-Romer, M Pallardy, I Cremer, L Peaudecerf, B Rocha, D Valteau-Couanet, JC Gutierrez, JA Nunes, F Commo, S Bonvalot, N Ibrahim, P Terrier, P Opolon, C Bottino, A Moretta, J Tavernier, P Rihet, JM Coindre, JY Blay, N Isambert, JF Emile, E Vivier, A Lecesne, G Kroemer and L Zitvogel: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med, 17(6), 700-7 (2011)
37. A Ito, TR Kataoka, DK Kim, Y Koma, YM Lee and Y Kitamura: Inhibitory effect on natural killer activity of microphthalmia transcription factor encoded by the mutant mi allele of mice. Blood, 97(7), 2075-83 (2001)
38. V Kumar, J Ben-Ezra, M Bennett and G Sonnenfeld: Natural killer cells in mice treated with 89strontium: normal target-binding cell numbers but inability to kill even after interferon administration. J Immunol, 123(4), 1832-8 (1979)
39. CA Vosshenrich, ME Garcia-Ojeda, SI Samson-Villeger, V Pasqualetto, L Enault, O Richard-Le Goff, E Corcuff, D Guy-Grand, B Rocha, A Cumano, L Rogge, S Ezine and JP Di Santo: A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol, 7(11), 1217-24 (2006)
40. AG Freud, B Becknell, S Roychowdhury, HC Mao, AK Ferketich, GJ Nuovo, TL Hughes, TB Marburger, J Sung, RA Baiocchi, M Guimond and MA Caligiuri: A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity, 22(3), 295-304 (2005)
41. DN Eissens, J Spanholtz, A van der Meer, B van Cranenbroek, H Dolstra, J Kwekkeboom, FW Preijers and I Joosten: Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One, 7(2), e30930 (2012)
42. Y Zhang, DL Wallace, CM de Lara, H Ghattas, B Asquith, A Worth, GE Griffin, GP Taylor, DF Tough, PC Beverley and DC Macallan: In vivo kinetics of human natural killer cells: The effects of ageing and acute and chronic viral infection. Immunology, 121(2), 258-65 (2007)
43. AM Jamieson, P Isnard, JR Dorfman, MC Coles and DH Raulet: Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol, 172(2), 864-70 (2004)
44. C Gregoire, L Chasson, C Luci, E Tomasello, F Geissmann, E Vivier and T Walzer: The trafficking of natural killer cells. Immunol Rev, 220, 169-82 (2007)
45. FD Shi, HG Ljunggren, A La Cava and L Van Kaer: Organ-specific features of natural killer cells. Nat Rev Immunol, 11(10), 658-71 (2011)
46. K Takeda, H Oshima, Y Hayakawa, H Akiba, M Atsuta, T Kobata, K Kobayashi, M Ito, H Yagita and K Okumura: CD27-mediated activation of murine NK cells. J Immunol, 164(4), 1741-5 (2000)
47. T Zhang, S Liu, P Yang, C Han, J Wang, J Liu, Y Han, Y Yu and X Cao: Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b/Src/betacatenin pathway. Blood, 114(19), 4081-8 (2009)
48. Y Hayakawa and MJ Smyth: CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol, 176(3), 1517-24 (2006)
49. L Chiossone, J Chaix, N Fuseri, C Roth, E Vivier and T Walzer: Maturation of mouse NK cells is a 4-stage developmental program. Blood, 113(22), 5488-96 (2009)
50. GP Downey, Q Dong, J Kruger, S Dedhar and V Cherapanov: Regulation of neutrophil activation in acute lung injury. Chest, 116(1 Suppl), 46S-54S (1999)
51. F Li, H Zhu, R Sun, H Wei and Z Tian: Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol, 86(4), 2251-8 (2012)
52. A Jemal, R Siegel, J Xu and E Ward: Cancer statistics, 2010. CA Cancer J Clin, 60(5), 277-300 (2010)
53. S Murala, V Alli, D Kreisel, AE Gelman and AS Krupnick: Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis, 2(4), 237-44 (2010)
54. FS Hodi, SJ O'Day, DF McDermott, RW Weber, JA Sosman, JB Haanen, R Gonzalez, C Robert, D Schadendorf, JC Hassel, W Akerley, AJ van den Eertwegh, J Lutzky, P Lorigan, JM Vaubel, GP Linette, D Hogg, CH Ottensmeier, C Lebbe, C Peschel, I Quirt, JI Clark, JD Wolchok, JS Weber, J Tian, MJ Yellin, GM Nichol, A Hoos and WJ Urba: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23 (2010)
55. DF McDermott, MM Regan, JI Clark, LE Flaherty, GR Weiss, TF Logan, JM Kirkwood, MS Gordon, JA Sosman, MS Ernstoff, CP Tretter, WJ Urba, JW Smith, KA Margolin, JW Mier, JA Gollob, JP Dutcher and MB Atkins: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol, 23(1), 133-41 (2005)
56. M Mohebtash, KY Tsang, RA Madan, NY Huen, DJ Poole, C Jochems, J Jones, T Ferrara, CR Heery, PM Arlen, SM Steinberg, M Pazdur, M Rauckhorst, EC Jones, WL Dahut, J Schlom and JL Gulley: A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res, 17(22), 7164-73 (2011)
57. RD Schreiber, LJ Old and MJ Smyth: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331(6024), 1565-70 (2011)
58. CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth and RD Schreiber: Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903-7 (2007)
59. S Platonova, J Cherfils-Vicini, D Damotte, L Crozet, V Vieillard, P Validire, P Andre, MC Dieu-Nosjean, M Alifano, JF Regnard, WH Fridman, C Sautes-Fridman and I Cremer: Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res, 71(16), 5412-22 (2011)
60. D Serraino, P Piselli, G Busnach, P Burra, F Citterio, E Arbustini, U Baccarani, E De Juli, U Pozzetto, S Bellelli, J Polesel, C Pradier, L Dal Maso, C Angeletti, MP Carrieri, G Rezza and S Franceschi: Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer, 43(14), 2117-23 (2007)
61. S Ikehara, RN Pahwa, G Fernandes, CT Hansen and RA Good: Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A, 81(3), 886-8 (1984)
62. T Hunig and MJ Bevan: Specificity of cytotoxic T cells from athymic mice. J Exp Med, 152(3), 688-702 (1980)
63. S Kobayashi, H Otsu and Y Noda: Comparison of lung tumorigenesis induced by urethan in athymic nude mice and euthymic littermates. Jikken Dobutsu, 43(3), 351-6 (1994)
64. S Kobayashi, H Otsu, Y Noda and T Ogiu: Comparison of dose-dependent enhancing effects of gamma-ray irradiation on urethan-induced lung tumorigenesis in athymic nude (nu/nu) mice ac (nu/+) littermates. J Cancer Res Clin Oncol, 122(4), 231-6 (1996)
65. Q Yang, SR Goding, ME Hokland and PH Basse: Antitumor activity of NK cells. Immunol Res, 36(1-3), 13-25 (2006)
66. HM Shaw, GW Milton, WH McCarthy, GA Farago and P Dilworth: Effect of smoking on the recurrence of malignant melanoma. Med J Aust, 1(6), 208-9 (1979)
67. M Ferson, A Edwards, A Lind, GW Milton and P Hersey: Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer, 23(5), 603-9 (1979)
68. W Pao and KE Hutchinson: Chipping away at the lung cancer genome. Nat Med, 18(3), 349-51 (2012)
69. LM Lu, CC Zavitz, B Chen, S Kianpour, Y Wan and MR Stampfli: Cigarette smoke impairs NK celldependent tumor immune surveillance. J Immunol, 178(2), 936-43 (2007)
70. L Chen, Z He, L Qin, Q Li, X Shi, S Zhao, N Zhong and X Chen: Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One, 6(9), e24407 (2011)
71. JS Orange: Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect, 4(15), 1545-58 (2002)
72. JS Orange, SR Brodeur, A Jain, FA Bonilla, LC Schneider, R Kretschmer, S Nurko, WL Rasmussen, JR Kohler, SE Gellis, BM Ferguson, JL Strominger, J Zonana, N Ramesh, ZK Ballas and RS Geha: Deficient natural killer cell cytotoxicity in patients with IKKgamma/ NEMO mutations. J Clin Invest, 109(11), 1501-9 (2002)
73. L Gineau, C Cognet, N Kara, FP Lach, J Dunne, U Veturi, C Picard, C Trouillet, C Eidenschenk, S Aoufouchi, A Alcais, O Smith, F Geissmann, C Feighery, L Abel, A Smogorzewska, B Stillman, E Vivier, JL Casanova and E Jouanguy: Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest, 122(3), 821-32 (2012)
74. CR Hughes, L Guasti, E Meimaridou, CH Chuang, JC Schimenti, PJ King, C Costigan, AJ Clark and LA Metherell: MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest, 122(3), 814-20 (2012)
75. C Eidenschenk, J Dunne, E Jouanguy, C Fourlinnie, L Gineau, D Bacq, C McMahon, O Smith, JL Casanova, L Abel and C Feighery: A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet, 78(4), 721-7 (2006)
76. SN Waggoner, M Cornberg, LK Selin and RM Welsh: Natural killer cells act as rheostats modulating antiviral T cells. Nature, 481(7381), 394-8 (2012)
77. J Stein-Streilein, J Guffee and W Fan: Locally and systemically derived natural killer cells participate in defense against intranasally inoculated influenza virus. Reg Immunol, 1(2), 100-5 (1988)
78. FA Ennis, A Meager, AS Beare, YH Qi, D Riley, G Schwarz, GC Schild and AH Rook: Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet, 2(8252), 891-3 (1981)
79. J Stein-Streilein and J Guffee: In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. J Immunol, 136(4), 1435-41 (1986)
80. O Mandelboim, N Lieberman, M Lev, L Paul, TI Arnon, Y Bushkin, DM Davis, JL Strominger, JW Yewdell and A Porgador: Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature, 409(6823), 1055-60 (2001)
81. JW Ho, O Hershkovitz, M Peiris, A Zilka, A Bar-Ilan, B Nal, K Chu, M Kudelko, YW Kam, H Achdout, M Mandelboim, R Altmeyer, O Mandelboim, R Bruzzone and A Porgador: H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol, 82(4), 2028-32 (2008)
82. WHO: Acute Respiratory Infections (Update September 2009). In, (2009)
83. S Elhaik-Goldman, D Kafka, R Yossef, U Hadad, M Elkabets, A Vallon-Eberhard, L Hulihel, S Jung, H Ghadially, A Braiman, RN Apte, O Mandelboim, R Dagan, Y Mizrachi-Nebenzahl and A Porgador: The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS One, 6(8), e23472 (2011)
84. VI Ayala, JR Teijaro, DL Farber, SG Dorsey and NH Carbonetti: Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity. PLoS One, 6(4), e19016 (2011)
85. R Vankayalapati, B Wizel, SE Weis, H Safi, DL Lakey, O Mandelboim, B Samten, A Porgador and PF Barnes: The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol, 168(7), 3451-7 (2002)
86. A Garg, PF Barnes, A Porgador, S Roy, S Wu, JS Nanda, DE Griffith, WM Girard, N Rawal, S Shetty and R Vankayalapati: Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol, 177(9), 6192-8 (2006)
87. P Schierloh, N Yokobori, M Aleman, RM Musella, M Beigier-Bompadre, MA Saab, L Alves, E Abbate, SS de la Barrera and MC Sasiain: Increased susceptibility to apoptosis of CD56dimCD16+ NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J Immunol, 175(10), 6852-60 (2005)